Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Authors
Keywords
-
Journal
BLOOD
Volume 122, Issue 15, Pages 2539-2549
Publisher
American Society of Hematology
Online
2013-07-26
DOI
10.1182/blood-2013-06-507947
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Selective Expression Rather than Specific Function of Txk and Itk Regulate Th1 and Th2 Responses
- (2014) N. Sahu et al. JOURNAL OF IMMUNOLOGY
- The B-cell receptor signaling pathway as a therapeutic target in CLL
- (2012) J. A. Woyach et al. BLOOD
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of Itk signalling in the interaction between influenza A virus and T-cells
- (2012) K. Fan et al. JOURNAL OF GENERAL VIROLOGY
- Abbott boosts investment in NRF2 activators for reducing oxidative stress
- (2012) Sarah Crunkhorn NATURE REVIEWS DRUG DISCOVERY
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- TEC family kinases in health and disease - loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK
- (2011) Alamdar Hussain et al. FEBS Journal
- Tec family kinases Itk and Rlk / Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates
- (2011) Julio Gomez-Rodriguez et al. FEBS Journal
- Enhanced Chromatin Accessibility and Recruitment of JUNB Mediate the Sustained IL-4 Expression in NFAT1 Deficient T Helper 2 Cells
- (2011) Jun-Seock Son et al. PLoS One
- The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
- (2011) Betty Y Chang et al. ARTHRITIS RESEARCH & THERAPY
- Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches
- (2010) Vicki A. Morrison BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Itk inhibitors: a patent review
- (2010) Ho Yin Lo EXPERT OPINION ON THERAPEUTIC PATENTS
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)
- (2009) D. I. Marks et al. BLOOD
- The Immune System and Cancer
- (2009) David Loose et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Circumventing Immune Tolerance Through Epigenetic Modification
- (2009) Jason Dubovsky et al. CURRENT PHARMACEUTICAL DESIGN
- Differential requirements for IL-4/STAT6 signalling in CD4 T-cell fate determination and Th2-immune effector responses
- (2009) Elizabeth Forbes et al. IMMUNOLOGY AND CELL BIOLOGY
- Selective targeting of ITK blocks multiple steps of HIV replication
- (2008) J. A. Readinger et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started